Paul Hudson, Getty Images
December 2, 2019 08:08 AM ESTUpdated 11:27 AM
R&D

Just days ahead of his big strate­gic re­veal, Sanofi CEO Paul Hud­son lines up a $350M sale

John Carroll

Editor & Founder

We won’t find out ex­act­ly what Paul Hud­son wants to fo­cus on in build­ing the fu­ture at Sanofi for an­oth­er 8 days, when he’s promised the big re­veal. But chances are what­ev­er he plans to con­cen­trate on, it won’t be the sur­gi­cal prod­ucts group at Seprafilm.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times